Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 180

1.

A phase I delayed-start, randomized and pharmacodynamic study of metformin and chemotherapy in patients with solid tumors.

Saif MW, Rajagopal S, Caplain J, Grimm E, Serebrennikova O, Das M, Tsichlis PN, Martell R.

Cancer Chemother Pharmacol. 2019 Oct 3. doi: 10.1007/s00280-019-03967-3. [Epub ahead of print]

PMID:
31583436
2.

The combination of TPL2 knockdown and TNFα causes synthetic lethality via caspase-8 activation in human carcinoma cell lines.

Serebrennikova OB, Paraskevopoulou MD, Aguado-Fraile E, Taraslia V, Ren W, Thapa G, Roper J, Du K, Croce CM, Tsichlis PN.

Proc Natl Acad Sci U S A. 2019 Jul 9;116(28):14039-14048. doi: 10.1073/pnas.1901465116. Epub 2019 Jun 25.

PMID:
31239343
3.

Severe fever with thrombocytopenia syndrome phlebovirus non-structural protein activates TPL2 signalling pathway for viral immunopathogenesis.

Choi Y, Park SJ, Sun Y, Yoo JS, Pudupakam RS, Foo SS, Shin WJ, Chen SB, Tsichlis PN, Lee WJ, Lee JS, Li W, Brennan B, Choi YK, Jung JU.

Nat Microbiol. 2019 Mar;4(3):429-437. doi: 10.1038/s41564-018-0329-x. Epub 2019 Jan 7.

4.

Genetic ablation of interacting with Spt6 (Iws1) causes early embryonic lethality.

Orlacchio A, Stark AE, Foray C, Amari F, Sheetz T, Reese E, Tessari A, La Perle K, Palmieri D, Tsichlis PN, Coppola V.

PLoS One. 2018 Sep 12;13(9):e0201030. doi: 10.1371/journal.pone.0201030. eCollection 2018.

5.

The Epigenetic Factor KDM2B Regulates EMT and Small GTPases in Colon Tumor Cells.

Zacharopoulou N, Tsapara A, Kallergi G, Schmid E, Alkahtani S, Alarifi S, Tsichlis PN, Kampranis SC, Stournaras C.

Cell Physiol Biochem. 2018;47(1):368-377. doi: 10.1159/000489917. Epub 2018 May 14.

6.

The epigenetic factor KDM2B regulates cell adhesion, small rho GTPases, actin cytoskeleton and migration in prostate cancer cells.

Zacharopoulou N, Tsapara A, Kallergi G, Schmid E, Tsichlis PN, Kampranis SC, Stournaras C.

Biochim Biophys Acta Mol Cell Res. 2018 Apr;1865(4):587-597. doi: 10.1016/j.bbamcr.2018.01.009. Epub 2018 Feb 2.

7.

Corrigendum: In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis.

Roper J, Tammela T, Cetinbas NM, Akkad A, Roghanian A, Rickelt S, Almeqdadi M, Wu K, Oberli MA, Sánchez-Rivera F, Park YK, Liang X, Eng G, Taylor MS, Azimi R, Kedrin D, Neupane R, Beyaz S, Sicinska ET, Suarez Y, Yoo J, Chen L, Zukerberg L, Katajisto P, Deshpande V, Bass AJ, Tsichlis PN, Lees J, Langer R, Hynes RO, Chen J, Bhutkar A, Jacks T, Yilmaz ÖH.

Nat Biotechnol. 2017 Dec 8;35(12):1211. doi: 10.1038/nbt1217-1211a.

PMID:
29220013
8.

A perspective on AKT 25-plus years after its discovery.

Paraskevopoulou MD, Tsichlis PN.

Sci Signal. 2017 Jul 4;10(486). pii: eaan8791. doi: 10.1126/scisignal.aan8791.

PMID:
28676491
9.
10.

In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis.

Roper J, Tammela T, Cetinbas NM, Akkad A, Roghanian A, Rickelt S, Almeqdadi M, Wu K, Oberli MA, Sánchez-Rivera FJ, Park YK, Liang X, Eng G, Taylor MS, Azimi R, Kedrin D, Neupane R, Beyaz S, Sicinska ET, Suarez Y, Yoo J, Chen L, Zukerberg L, Katajisto P, Deshpande V, Bass AJ, Tsichlis PN, Lees J, Langer R, Hynes RO, Chen J, Bhutkar A, Jacks T, Yilmaz ÖH.

Nat Biotechnol. 2017 Jun;35(6):569-576. doi: 10.1038/nbt.3836. Epub 2017 May 1. Erratum in: Nat Biotechnol. 2017 Dec 8;35(12 ):1211.

11.

Proline hydroxylation linked to Akt activation.

Voulgarelis M, Tsichlis PN.

Science. 2016 Aug 26;353(6302):870-1. doi: 10.1126/science.aah6254. No abstract available.

PMID:
27563086
12.

TPL2 Kinase Is a Crucial Signaling Factor and Mediator of NKT Effector Cytokine Expression in Immune-Mediated Liver Injury.

Vyrla D, Nikolaidis G, Oakley F, Perugorria MJ, Tsichlis PN, Mann DA, Eliopoulos AG.

J Immunol. 2016 May 15;196(10):4298-310. doi: 10.4049/jimmunol.1501609. Epub 2016 Apr 6.

13.

MicroRNA214 Is Associated With Progression of Ulcerative Colitis, and Inhibition Reduces Development of Colitis and Colitis-Associated Cancer in Mice.

Polytarchou C, Hommes DW, Palumbo T, Hatziapostolou M, Koutsioumpa M, Koukos G, van der Meulen-de Jong AE, Oikonomopoulos A, van Deen WK, Vorvis C, Serebrennikova OB, Birli E, Choi J, Chang L, Anton PA, Tsichlis PN, Pothoulakis C, Verspaget HW, Iliopoulos D.

Gastroenterology. 2015 Oct;149(4):981-92.e11. doi: 10.1053/j.gastro.2015.05.057. Epub 2015 Jun 6.

14.

Toll-like receptor 2-dependent extracellular signal-regulated kinase signaling in Mycobacterium tuberculosis-infected macrophages drives anti-inflammatory responses and inhibits Th1 polarization of responding T cells.

Richardson ET, Shukla S, Sweet DR, Wearsch PA, Tsichlis PN, Boom WH, Harding CV.

Infect Immun. 2015 Jun;83(6):2242-54. doi: 10.1128/IAI.00135-15. Epub 2015 Mar 16.

15.

Physical and functional interaction of the TPL2 kinase with nucleophosmin.

Kanellis DC, Bursac S, Tsichlis PN, Volarevic S, Eliopoulos AG.

Oncogene. 2015 May 7;34(19):2516-26. doi: 10.1038/onc.2014.183. Epub 2014 Jul 7.

PMID:
24998852
16.

NDY1/KDM2B functions as a master regulator of polycomb complexes and controls self-renewal of breast cancer stem cells.

Kottakis F, Foltopoulou P, Sanidas I, Keller P, Wronski A, Dake BT, Ezell SA, Shen Z, Naber SP, Hinds PW, McNiel E, Kuperwasser C, Tsichlis PN.

Cancer Res. 2014 Jul 15;74(14):3935-46. doi: 10.1158/0008-5472.CAN-13-2733. Epub 2014 May 22.

17.

The downregulation of GFI1 by the EZH2-NDY1/KDM2B-JARID2 axis and by human cytomegalovirus (HCMV) associated factors allows the activation of the HCMV major IE promoter and the transition to productive infection.

Sourvinos G, Morou A, Sanidas I, Codruta I, Ezell SA, Doxaki C, Kampranis SC, Kottakis F, Tsichlis PN.

PLoS Pathog. 2014 May 15;10(5):e1004136. doi: 10.1371/journal.ppat.1004136. eCollection 2014 May.

18.

Regulation of experimental autoimmune encephalomyelitis by TPL-2 kinase.

Sriskantharajah S, Gückel E, Tsakiri N, Kierdorf K, Brender C, Ben-Addi A, Veldhoen M, Tsichlis PN, Stockinger B, O'Garra A, Prinz M, Kollias G, Ley SC.

J Immunol. 2014 Apr 15;192(8):3518-3529. doi: 10.4049/jimmunol.1300172. Epub 2014 Mar 17.

19.

Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.

Roper J, Sinnamon MJ, Coffee EM, Belmont P, Keung L, Georgeon-Richard L, Wang WV, Faber AC, Yun J, Yilmaz ÖH, Bronson RT, Martin ES, Tsichlis PN, Hung KE.

Cancer Lett. 2014 Jun 1;347(2):204-11. doi: 10.1016/j.canlet.2014.02.018. Epub 2014 Feb 24.

20.

Stat5 regulates the phosphatidylinositol 3-kinase/Akt1 pathway during mammary gland development and tumorigenesis.

Schmidt JW, Wehde BL, Sakamoto K, Triplett AA, Anderson SM, Tsichlis PN, Leone G, Wagner KU.

Mol Cell Biol. 2014 Apr;34(7):1363-77. doi: 10.1128/MCB.01220-13. Epub 2014 Jan 27.

21.

Phosphoproteomics screen reveals akt isoform-specific signals linking RNA processing to lung cancer.

Sanidas I, Polytarchou C, Hatziapostolou M, Ezell SA, Kottakis F, Hu L, Guo A, Xie J, Comb MJ, Iliopoulos D, Tsichlis PN.

Mol Cell. 2014 Feb 20;53(4):577-90. doi: 10.1016/j.molcel.2013.12.018. Epub 2014 Jan 23.

22.

AKT3 controls mitochondrial biogenesis and autophagy via regulation of the major nuclear export protein CRM-1.

Corum DG, Tsichlis PN, Muise-Helmericks RC.

FASEB J. 2014 Jan;28(1):395-407. doi: 10.1096/fj.13-235382. Epub 2013 Sep 30.

23.

Tpl2 kinase regulates FcγR signaling and immune thrombocytopenia in mice.

Kyrmizi I, Ioannou M, Hatziapostolou M, Tsichlis PN, Boumpas DT, Tassiulas I.

J Leukoc Biol. 2013 Oct;94(4):751-7. doi: 10.1189/jlb.0113039. Epub 2013 Jul 29.

24.

Loss of ARF sensitizes transgenic BRAFV600E mice to UV-induced melanoma via suppression of XPC.

Luo C, Sheng J, Hu MG, Haluska FG, Cui R, Xu Z, Tsichlis PN, Hu GF, Hinds PW.

Cancer Res. 2013 Jul 15;73(14):4337-48. doi: 10.1158/0008-5472.CAN-12-4454. Epub 2013 May 6.

25.

TPL2 kinase is a suppressor of lung carcinogenesis.

Gkirtzimanaki K, Gkouskou KK, Oleksiewicz U, Nikolaidis G, Vyrla D, Liontos M, Pelekanou V, Kanellis DC, Evangelou K, Stathopoulos EN, Field JK, Tsichlis PN, Gorgoulis V, Liloglou T, Eliopoulos AG.

Proc Natl Acad Sci U S A. 2013 Apr 16;110(16):E1470-9. doi: 10.1073/pnas.1215938110. Epub 2013 Mar 26.

26.

Akt1, EMSY, BRCA2 and type I IFN signaling: a novel arm of the IFN response.

Ezell SA, Tsichlis PN.

Transcription. 2012 Nov-Dec;3(6):305-9. doi: 10.4161/trns.21904. Epub 2012 Nov 1.

27.

Akt1 and Akt2 protein kinases differentially contribute to macrophage polarization.

Arranz A, Doxaki C, Vergadi E, Martinez de la Torre Y, Vaporidi K, Lagoudaki ED, Ieronymaki E, Androulidaki A, Venihaki M, Margioris AN, Stathopoulos EN, Tsichlis PN, Tsatsanis C.

Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9517-22. doi: 10.1073/pnas.1119038109. Epub 2012 May 30.

28.

Tpl2 ablation promotes intestinal inflammation and tumorigenesis in Apcmin mice by inhibiting IL-10 secretion and regulatory T-cell generation.

Serebrennikova OB, Tsatsanis C, Mao C, Gounaris E, Ren W, Siracusa LD, Eliopoulos AG, Khazaie K, Tsichlis PN.

Proc Natl Acad Sci U S A. 2012 May 1;109(18):E1082-91. doi: 10.1073/pnas.1115098109. Epub 2012 Mar 26.

29.

The protein kinase Akt1 regulates the interferon response through phosphorylation of the transcriptional repressor EMSY.

Ezell SA, Polytarchou C, Hatziapostolou M, Guo A, Sanidas I, Bihani T, Comb MJ, Sourvinos G, Tsichlis PN.

Proc Natl Acad Sci U S A. 2012 Mar 6;109(10):E613-21. doi: 10.1073/pnas.1115029109. Epub 2012 Feb 6.

30.

The NF-κB1 transcription factor prevents the intrathymic development of CD8 T cells with memory properties.

Gugasyan R, Horat E, Kinkel SA, Ross F, Grigoriadis G, Gray D, O'Keeffe M, Berzins SP, Belz GT, Grumont RJ, Banerjee A, Strasser A, Godfrey DI, Tsichlis PN, Gerondakis S.

EMBO J. 2012 Feb 1;31(3):692-706. doi: 10.1038/emboj.2011.435. Epub 2011 Nov 29.

31.

Tumor progression locus 2 mediates signal-induced increases in cytoplasmic calcium and cell migration.

Hatziapostolou M, Koukos G, Polytarchou C, Kottakis F, Serebrennikova O, Kuliopulos A, Tsichlis PN.

Sci Signal. 2011 Aug 23;4(187):ra55. doi: 10.1126/scisignal.2002006.

32.

FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2B-miR-101-EZH2 pathway.

Kottakis F, Polytarchou C, Foltopoulou P, Sanidas I, Kampranis SC, Tsichlis PN.

Mol Cell. 2011 Jul 22;43(2):285-98. doi: 10.1016/j.molcel.2011.06.020.

33.

Akt2 regulates all Akt isoforms and promotes resistance to hypoxia through induction of miR-21 upon oxygen deprivation.

Polytarchou C, Iliopoulos D, Hatziapostolou M, Kottakis F, Maroulakou I, Struhl K, Tsichlis PN.

Cancer Res. 2011 Jul 1;71(13):4720-31. doi: 10.1158/0008-5472.CAN-11-0365. Epub 2011 May 9.

34.

Tumor progression locus 2 (TPL2) regulates obesity-associated inflammation and insulin resistance.

Perfield JW 2nd, Lee Y, Shulman GI, Samuel VT, Jurczak MJ, Chang E, Xie C, Tsichlis PN, Obin MS, Greenberg AS.

Diabetes. 2011 Apr;60(4):1168-76. doi: 10.2337/db10-0715. Epub 2011 Feb 23.

35.

Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells.

Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, Struhl K.

Mol Cell. 2010 Sep 10;39(5):761-72. doi: 10.1016/j.molcel.2010.08.013.

36.

A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases.

Hirsch HA, Iliopoulos D, Joshi A, Zhang Y, Jaeger SA, Bulyk M, Tsichlis PN, Shirley Liu X, Struhl K.

Cancer Cell. 2010 Apr 13;17(4):348-61. doi: 10.1016/j.ccr.2010.01.022.

37.

Ablation of tumor progression locus 2 promotes a type 2 Th cell response in Ovalbumin-immunized mice.

Watford WT, Wang CC, Tsatsanis C, Mielke LA, Eliopoulos AG, Daskalakis C, Charles N, Odom S, Rivera J, O'Shea J, Tsichlis PN.

J Immunol. 2010 Jan 1;184(1):105-13. doi: 10.4049/jimmunol.0803730. Epub 2009 Dec 2.

38.

Tumor progression locus 2 (Map3k8) is critical for host defense against Listeria monocytogenes and IL-1 beta production.

Mielke LA, Elkins KL, Wei L, Starr R, Tsichlis PN, O'Shea JJ, Watford WT.

J Immunol. 2009 Dec 15;183(12):7984-93. doi: 10.4049/jimmunol.0901336.

39.

MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells.

Iliopoulos D, Polytarchou C, Hatziapostolou M, Kottakis F, Maroulakou IG, Struhl K, Tsichlis PN.

Sci Signal. 2009 Oct 13;2(92):ra62. doi: 10.1126/scisignal.2000356.

40.

Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission.

Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K.

Cancer Res. 2009 Oct 1;69(19):7507-11. doi: 10.1158/0008-5472.CAN-09-2994. Epub 2009 Sep 14. Erratum in: Cancer Res. 2009 Nov 15;69(22):8832.

41.

The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs.

Androulidaki A, Iliopoulos D, Arranz A, Doxaki C, Schworer S, Zacharioudaki V, Margioris AN, Tsichlis PN, Tsatsanis C.

Immunity. 2009 Aug 21;31(2):220-31. doi: 10.1016/j.immuni.2009.06.024.

42.

TPL-2 negatively regulates interferon-beta production in macrophages and myeloid dendritic cells.

Kaiser F, Cook D, Papoutsopoulou S, Rajsbaum R, Wu X, Yang HT, Grant S, Ricciardi-Castagnoli P, Tsichlis PN, Ley SC, O'Garra A.

J Exp Med. 2009 Aug 31;206(9):1863-71. doi: 10.1084/jem.20091059. Epub 2009 Aug 10.

43.

Histone demethylases and cancer.

Kampranis SC, Tsichlis PN.

Adv Cancer Res. 2009;102:103-69. doi: 10.1016/S0065-230X(09)02004-1. Review.

44.

Ndy1/KDM2B immortalizes mouse embryonic fibroblasts by repressing the Ink4a/Arf locus.

Tzatsos A, Pfau R, Kampranis SC, Tsichlis PN.

Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2641-6. doi: 10.1073/pnas.0813139106. Epub 2009 Feb 6.

45.

A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis.

Hu MG, Deshpande A, Enos M, Mao D, Hinds EA, Hu GF, Chang R, Guo Z, Dose M, Mao C, Tsichlis PN, Gounari F, Hinds PW.

Cancer Res. 2009 Feb 1;69(3):810-8. doi: 10.1158/0008-5472.CAN-08-2473. Epub 2009 Jan 20.

46.

Tpl2 kinase regulates T cell interferon-gamma production and host resistance to Toxoplasma gondii.

Watford WT, Hissong BD, Durant LR, Yamane H, Muul LM, Kanno Y, Tato CM, Ramos HL, Berger AE, Mielke L, Pesu M, Solomon B, Frucht DM, Paul WE, Sher A, Jankovic D, Tsichlis PN, O'Shea JJ.

J Exp Med. 2008 Nov 24;205(12):2803-12. doi: 10.1084/jem.20081461. Epub 2008 Nov 10.

47.

The JmjC domain histone demethylase Ndy1 regulates redox homeostasis and protects cells from oxidative stress.

Polytarchou C, Pfau R, Hatziapostolou M, Tsichlis PN.

Mol Cell Biol. 2008 Dec;28(24):7451-64. doi: 10.1128/MCB.00688-08. Epub 2008 Oct 6.

48.

Distinct roles of the three Akt isoforms in lactogenic differentiation and involution.

Maroulakou IG, Oemler W, Naber SP, Klebba I, Kuperwasser C, Tsichlis PN.

J Cell Physiol. 2008 Nov;217(2):468-77. doi: 10.1002/jcp.21518.

49.

VEGF stimulation of mitochondrial biogenesis: requirement of AKT3 kinase.

Wright GL, Maroulakou IG, Eldridge J, Liby TL, Sridharan V, Tsichlis PN, Muise-Helmericks RC.

FASEB J. 2008 Sep;22(9):3264-75. doi: 10.1096/fj.08-106468. Epub 2008 Jun 4.

50.

Proteinase-activated receptor-1-triggered activation of tumor progression locus-2 promotes actin cytoskeleton reorganization and cell migration.

Hatziapostolou M, Polytarchou C, Panutsopulos D, Covic L, Tsichlis PN.

Cancer Res. 2008 Mar 15;68(6):1851-61. doi: 10.1158/0008-5472.CAN-07-5793.

Supplemental Content

Loading ...
Support Center